FCX vs STRO
Freeport-McMoran Copper & Gold Inc (FCX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported FCX revenue for 2024-12-31 was $25.45B. Net income was $4.40B. Revenue was up 11.4% from 2023-12-31 to 2024-12-31. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. STRO currently screens at market cap $470.8M.
Not investment advice. Open the FCX and STRO stock pages for the full models.
Not investment advice.